Want early access to the study?

Download a multinational study on AAT augmentation therapy. This research demonstrates the significant1 survival benefits of intravenous alpha-antitrypsin (AAT) augmentation therapy for patients with alpha-antitrypsin deficiency (AATD), a condition that leads to progressive lung damage. By attending our symposium at the ERS Congress, you’ll gain insights into these findings and learn how they can shape your approach to care.

Download the study now

Fill out the form below and instantly receive the full study on AAT augmentation therapy and its impact on survival.

Speak to us at the ERS Congress

Visit our booth at the ERS Congress - Join us in Amsterdam from 27 September ➞ 1 October

WATCH

Insights on AAT Augmentation Therapy & Survival

Explore the key findings from the multinational study on the benefits of intravenous AAT augmentation therapy in improving survival and lung function for patients with AATD.

Get the Full Study Delivered to Your Inbox

Fill out the form below to download the complete study on AAT augmentation therapy. We look forward to seeing you at the ERS Congress in September.

Sign Up

All fields are required unless otherwise stated

Data Protection Information
The Grifols' group company to which you submit the request, as data controller, will process your personal data to provide information about our products. The legal basis is your consent. Your data may be shared with Grifols' group companies and other third parties. You have the right to access, rectify and erase, as well as any other rights detailed in the additional information. For additional information on personal data protection check here.

By clicking the button below, I agree that my data will be used as described in this form.

References

  1. Fraughen DD, Ghosh AJ, Hobbs BD, et al. Augmentation therapy for severe alpha-1 antitrypsin deficiency improves survival and is decoupled from spirometric decline-A multinational registry analysis. Am J Respir Crit Care Med. 2023;208(9):964-974.